Autonomous AI can increase clinical capacity for dermatologists
Autonomous artificial intelligence (AI) in urgent skin cancer pathways can increase clinical capacity for dermatologists, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 30 to Oct. 3 in Vienna.
A groundbreaking study revealed that autonomous artificial intelligence (AI) can significantly boost the clinical capacity of dermatologists, particularly in urgent skin cancer cases. Presented at the European Academy of Dermatology and Venereology's annual meeting in Vienna, the research showed that class III AIaMD increased clinical capacity by 62% when implemented across two hospital sites.
Lucy Thomas, M.B.Ch.B. from Imperial College London, led the study, which involved sequential validation of AIaMD, followed by hierarchical classification prioritizing higher-risk diagnoses. In the autonomous AIaMD pathway, 8,391 patients were managed, with a consent rate of 86%. Astonishingly, 37% and 32% of patients were discharged autonomously at site 1 and site 2, respectively, while an additional 24% and 25% were discharged by teledermatologists (TD) at the same sites.
The study found that autonomous AIaMD reduced routine follow-up by 12% compared to standard TD and decreased biopsy rates from 43% to 29% compared with conventional face-to-face care. False negatives were rare, and no adverse outcomes were identified within the available follow-up.
Thomas emphasized that the greatest value of autonomous AI lies not in the technology itself but in the specialist capacity it unlocks. The findings demonstrate that AI can significantly increase clinical capacity for dermatologists in urgent skin cancer pathways without compromising patient safety.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
